@article{ae36bfd6d8d441db9d42284582962a11,
title = "Plasma T790M result alters treatment options in a previously T790 wild-type EGFR-mutant lung cancer",
author = "Zofia Piotrowska and Benjamin Drapkin and Engelman, {Jeffrey A.} and Nagy, {Rebecca J.} and Lanman, {Richard B.} and Sequist, {Lecia V.}",
note = "Funding Information: Dr. Engelman received a National Institutes of Health–National Cancer Institute grant ( R01 CA137008 ) during the conduct of this study. Funding Information: Disclosure: Dr. Piotrowska reports personal fees from Clovis Oncology, Boehringer-Ingelheim, and AstraZeneca outside the submitted work. Dr. Engelman reports grants, personal fees, and nonfinancial support from Novartis and AstraZeneca; personal fees and nonfinancial support from Clovis; and other support from Gatekeeper outside the submitted work. In addition, Dr. Engelman has a patent, International Patent Application PCT/US2008/004804. Ms. Nagy reports being an employee and stockholder of Guardant Health during conduct of this study and outside the submitted work. Dr. Lanman reports being an employee and stockholder of Guardant Health, Inc., during conduct of this study. Dr. Sequist reports uncompensated consulting for Clovis Oncology, Novartis, Merrimack, and Taiho and consulting for AstraZeneca and Ariad outside the submitted work. The remaining author declares no conflict of interest. ",
year = "2016",
doi = "10.1016/j.jtho.2016.03.020",
language = "English (US)",
volume = "11",
pages = "e95--e97",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "8",
}